LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL

Conference contribution


Publication Details

Author(s): Stone JH, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony S
Publisher: BMJ PUBLISHING GROUP
Publishing place: LONDON
Publication year: 2019
Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES
Pages range: 145-146
ISSN: 0003-4967
eISSN: 1468-2060


External institutions with authors

Arcispedale Santa Maria Nuova
Genentech Inc.
Harvard University
Hospital for Special Surgery (HSS)
Southend University Hospital NHS Foundation Trust
Universitat de Barcelona (UB) / University of Barcelona
Universitätsklinikum Carl Gustav Carus Dresden
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
University of Groningen / Rijksuniversiteit Groningen


How to cite

APA:
Stone, J.H., Bao, M., Han, J., Aringer, M., Blockmans, D., Brouwer, E.,... Unizony, S. (2019). LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL. In ANNALS OF THE RHEUMATIC DISEASES (pp. 145-146). Madrid, ES: LONDON: BMJ PUBLISHING GROUP.

MLA:
Stone, John H., et al. "LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL." Proceedings of the Annual European Congress of Rheumatology (EULAR), Madrid LONDON: BMJ PUBLISHING GROUP, 2019. 145-146.

BibTeX: 

Last updated on 2019-16-07 at 08:39